Product Data Sheet

(Pro3) GIP, human TFA

Cat. No.:	HY-P3584A	
Molecular Formula:	C ₂₂₆ H ₃₃₈ N ₆₀ O ₆₄ S.xC ₂ HF ₃ O ₂	
Sequence:	Tyr-Ala-Pro-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp- Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gl n	
Sequence Shortening:	YAPGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ	
Target:	Insulin Receptor	
Pathway:	Protein Tyrosine Kinase/RTK	
Storage:	Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 month; -20°C, 1 month (sealed storage, away from moisture and light)	

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (Need ultrasonic)
	$H_2O: \ge 100 \text{ mg/mL}$
	* "≥" means soluble, but saturation unknown.

BIOLOGICAL ACTIVITY

Description (Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with K_i/ K_d value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes^{[1][2]}.

REFERENCES

[1]. Victor A Gault, et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes. 2005, 54, 8.

[2]. A H Sparre-Ulrich, et al. Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br J Pharmacol. 2016, 173, 1.

Caution: Product has not been fully validated for medical applications. For research use only.

```
Tel: 609-228-6898
```

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA